Minnesota House File 4852: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Minnesota · 2025-2026 session

Status: In committee

Latest action

Introduction and first reading, referred to Health Finance and Policy (2026-04-07)